Conditional market approval for recombinant shots
Print Edition
THE Chinese National Medical Products Administration granted conditional market approval to a recombinant novel coronavirus vaccine that requires only one shot.
Developed by a research team led by Chen Wei, an academician at the Chinese Academy of Engineering and a researcher at the Institute of Military Medicine under the Academy of Military Sciences, it is China’s first approved COVID-19 vaccine that relies on adenovirus as the vector to deliver the coronavirus spike gene into the body.
Targeting people aged above 18, the vaccine can be transported and stored at a temperature ranging from 2 to 8 degrees Celsius. The vaccine shows a 65.7 percent efficacy at preventing symptomatic cases and a 90.98 percent efficacy against severe disease.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
